Abvc biopharma provides vitargus® update - phase ii vitargus® study protocol received thai fda approval

Fremont, ca, nov. 17, 2022 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, today announced that the vitargus® phase ii clinical study protocol has been approved by the thailand food and drug administration (fda). import licenses for the vitargus medical device and sf6-gas used as a comparator in the clinical study were issued to both th001 and th002 study sites in thailand on november 2, 2022.
ABVC Ratings Summary
ABVC Quant Ranking